Jessica Fye

Paul Choi

Kyuwon Choi

Maizi Ali Mohamed

Mazahir Alimohamed

Mazi Alimohamed

- Amarin reported **total net revenue of $49.7 million** in Q3 2025, a **17% increase** year-over-year, driven by a **34% increase in U.S. net product revenue to $40.9 million**.  **[0000897448_2211102_5]** 
- The company significantly improved its financial discipline, with a **Q3 2025 operating loss of $11.1 million**, a **56% reduction** from Q3 2024, and an operating margin of **negative 22%**, up from negative 60% in the prior year.  **[0000897448_2211102_6]** 
- Amarin has transitioned to a **fully partnered commercial model across international ex-U.S. markets**, notably with Recordati in Europe, and implemented an organizational restructuring expected to yield **$70 million in OpEx savings over the next year**.  **[0000897448_2211102_1]** **[0000897448_2211102_2]** **[0000897448_2211102_5]** 
- The company anticipates achieving **positive free cash flow in 2026** and ended Q3 2025 with **$286.6 million in cash and investments** and no debt.  **[0000897448_2211102_6]** 
- The FDA's recent revision of phenofibrate labeling, stating no cardiovascular benefit, is viewed as a **critical step toward shifting clinical practice** and an opportunity for VASCEPA, which has proven outcomes.  **[0000897448_2211102_3]** **[0000897448_2211102_4]** **[0000897448_2211102_9]**

Amarin Reports Q3 2025 Financial Results and Strategic Progress

- Amarin reported **total net revenue of $49.7 million** for Q3 2025, marking a **17% increase** year-over-year, primarily driven by a **34% rise in U.S. net product revenue to $40.9 million**.  **[0000897448_2215666_5]** 
- The company's operating loss significantly improved to **$11.1 million**, a **56% reduction** from Q3 2024, with operating margin improving to **-22%** from -60% in the prior year, largely due to a **47% reduction in SG&A** from global restructuring.  **[0000897448_2215666_5]** **[0000897448_2215666_6]** 
- Amarin is progressing with its **fully partnered commercial model** across international ex-U.S. markets, with the European transition to Recordati on track for completion by year-end 2025.  **[0000897448_2215666_1]** **[0000897448_2215666_5]** 
- The company ended the quarter with **$286.6 million in cash and investments** and no debt, and anticipates achieving **positive free cash flow in 2026**.  **[0000897448_2215666_6]**

Amarin Reports Q3 2025 Financial Results with Revenue Growth and Improved Operating Loss

- Amarin reported **Q3 2025 total net revenue of $49.7 million**, a **17% increase** year-over-year, driven by a **34% increase** in U.S. net product revenue to **$40.9 million**.  **[0000897448_2215567_5]**  The company's operating loss significantly improved to **$11.1 million**, **56% lower** than Q3 2024.  **[0000897448_2215567_6]** 
- The company has transitioned to a **fully partnered commercial model** across international ex-U.S. markets, with Recordati expected to fully manage European commercialization by the **end of 2025**.  **[0000897448_2215567_1]**  This strategic shift, combined with an organizational restructuring, is projected to yield **$70 million in OpEx savings** over the next year.  **[0000897448_2215567_1]** 
- Amarin maintains **over 50% share** of the U.S. IPE market and regained exclusive status with a large national pharmacy benefit manager, expecting to retain major exclusives through at least the **end of 2025**.  **[0000897448_2215567_2]** 
- The company anticipates achieving **positive free cash flow in 2026** and ended Q3 2025 with **$286.6 million in cash and investments** and no debt.  **[0000897448_2215567_6]** 
- The FDA's recent revision of phenofibrate labeling, highlighting a **lack of cardiovascular benefit**, is seen by Amarin as a critical step that could shift clinical practice towards proven therapies like VASCEPA.  **[0000897448_2215567_3]** **[0000897448_2215567_9]**

Amarin Reports Q3 2025 Financial Results and Progresses on Partnered Commercial Model

- Amarin reported **Total Net Revenue** of **$49.7 million** for Q3 2025, an **increase of 17%** compared to Q3 2024, primarily driven by higher U.S. sales.  **[897448_0001193125-25-254620_amrn-ex99_1.htm:0]** **[897448_0001193125-25-254620_amrn-ex99_1.htm:1]** 
- **Operating Expenses** decreased **20%** to **$33.3 million** in Q3 2025, leading to an **Operating Loss** of **$11.1 million**, a **56% improvement** from Q3 2024, largely due to the June 2025 restructuring.  **[897448_0001193125-25-254620_amrn-ex99_1.htm:0]** **[897448_0001193125-25-254620_amrn-ex99_1.htm:1]** 
- The company's **Net Loss** for Q3 2025 was **$7.7 million**, or **$0.02 per share**, representing a **69% improvement** compared to Q3 2024.  **[897448_0001193125-25-254620_amrn-ex99_1.htm:0]** **[897448_0001193125-25-254620_amrn-ex99_1.htm:1]** 
- Amarin held **$286.6 million** in cash and investments at the end of Q3 2025.  **[897448_0001193125-25-254620_amrn-ex99_1.htm:0]** **[897448_0001193125-25-254620_amrn-ex99_1.htm:1]** 
- The company is **targeting sustainable positive free cash flow in 2026** and has completed its transition to a fully partnered commercialization model across all international markets.  **[897448_0001193125-25-254620_amrn-ex99_1.htm:0]**

AMARIN CORP PLC\UK (AMRN)